Clinical trials in Chemnitz – page 4

209 clinical trials in Chemnitz, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Chemnitz at a glance

209

clinical trials

Research sites0

Quick filters

209 trials in Chemnitz

Open in trial search

Pancreatic carcinoma metastatic+1

Recruiting

A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

Registered drug

A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Gemcitabine
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Dermatitis atopic

Recruiting

A study to evaluate the long-term safety and effectiveness of afimkibart in patients with atopic dermatitis who took part in previous afimkibart studies

Investigational

A study to evaluate the long-term safety and effectiveness of afimkibart in patients with atopic dermatitis who took part in previous afimkibart studies

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:RO7790121
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Gastrooesophageal cancer+1

Recruiting

A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

Registered drugNo placebo

A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Fruquintinib
Sponsor:Fondation Franc.Cancerologie Digestive

Contact Research Centre

Major depression

Recruiting

A Study of Brexanolone Caprilcerbate for Adults with Major Depressive Disorder With or Without Anxious Distress

InvestigationalNo placebo

A Study of Brexanolone Caprilcerbate for Adults with Major Depressive Disorder With or Without Anxious Distress

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Sponsor:Seaport Therapeutics Inc.

Contact Research Centre

Central nervous system lymphoma

Recruiting

Study of Lisocabtagene Maraleucel as First Treatment for Adults with Primary Central Nervous System Lymphoma Who Cannot Have a Stem Cell Transplant

Registered drugNo placebo

Study of Lisocabtagene Maraleucel as First Treatment for Adults with Primary Central Nervous System Lymphoma Who Cannot Have a Stem Cell Transplant

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Dementia Alzheimer's type

Recruiting

Study of KarXT (trospium chloride and xanomeline tartrate) and KarX-EC (xanomeline tartrate) for cognitive impairment in mild to moderate Alzheimer's disease

Investigational

Study of KarXT (trospium chloride and xanomeline tartrate) and KarX-EC (xanomeline tartrate) for cognitive impairment in mild to moderate Alzheimer's disease

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Trospium Chloride
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Small cell lung cancer recurrent

Recruiting

Study comparing GSK5764227 and topotecan in adults with relapsed small cell lung cancer

Registered drugNo placebo

Study comparing GSK5764227 and topotecan in adults with relapsed small cell lung cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:GSK5764227
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Mantle cell lymphoma

Recruiting

Study of Glofitamab and Pirtobrutinib Treatment in Patients with Mantle Cell Lymphoma Who Have Failed Previous Therapy and in Previously Untreated Patients

Registered drugNo placebo

Study of Glofitamab and Pirtobrutinib Treatment in Patients with Mantle Cell Lymphoma Who Have Failed Previous Therapy and in Previously Untreated Patients

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Glofitamab
Sponsor:Klinikum der Universitaet Muenchen AöR

Contact Research Centre

Acute myeloid leukaemia+3

Recruiting

Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

Registered drugNo placebo

Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Busulfan
Sponsor:Medizinische Hochschule Hannover

Contact Research Centre

Diffuse large B-cell lymphoma+2

Recruiting

Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

Registered drugNo placebo

Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Universitaet Muenster

Contact Research Centre

Hodgkin's disease

Recruiting

Study of pembrolizumab with drug combination for first-line treatment in patients with advanced-stage classic Hodgkin lymphoma

Registered drugNo placebo

Study of pembrolizumab with drug combination for first-line treatment in patients with advanced-stage classic Hodgkin lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years
Substances:Brentuximab Vedotin
Sponsor:University Of Cologne

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Bicara Therapeutics Inc.

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Chemnitz

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on lymphomas and leukemias, including studies evaluating novel therapies for chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and acute myeloid leukemia.

Multiple myeloma treatments
B-cell lymphoma therapies
Leukemia interventions

Several trials are investigating combination therapies and targeted treatments to improve patient outcomes.

02 Solid Tumor Research

Groundbreaking studies in gastric cancer and breast cancer, with particular emphasis on HER2-positive tumors and targeted therapeutic approaches.

Colorectal cancer treatments
Melanoma therapies
Glioblastoma interventions

Focus on personalized medicine approaches and combination treatments for various solid tumors.

03 Autoimmune Conditions

Clinical investigations of treatments for Sjögren's Syndrome and other autoimmune disorders, exploring new therapeutic options for patients.

Atopic dermatitis treatments
Prurigo nodularis studies
Inflammatory conditions

Evaluating novel compounds and biologics for chronic autoimmune conditions.

Back to Germany All countries